Medroxyprogesterone Acetate Tablet shortage
Medroxyprogesterone Acetate Tablet is currently listed in shortage by the FDA. The FDA lists 2 affected products. This page was last refreshed from FDA data on Oct 3, 2026.
Pfizer is stopping production of medroxyprogesterone acetate tablets, with withdrawal from sale expected by late 2026. Other makers still list this medicine — including Provera (medroxyprogesterone acetate) — so it may be available from other sources.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Medroxyprogesterone Acetate Tablet. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Aug 31, 2026Currently in shortage2 of 2 products affected.
-
Aug 31, 2026First reported to the FDA2 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Pfizer Inc. 📞 800-533-4535 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | PROVERA, Tablet, 2.5 mg (NDC 0009-0065-01) | — | — | Discontinuation of the manufacture of the drug; Withdrawal from sale expected early October 2026. | — |
| To Be Discontinued | PROVERA, Tablet, 10 mg (NDC 0009-0051-01) | — | — | Discontinuation of the manufacture of the drug; Withdrawal from sale expected September 2026. | — |
These rows are manufacturer reports to the FDA for Medroxyprogesterone Acetate Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Medroxyprogesterone Acetate Tablet? options further down this page.
Why is Medroxyprogesterone Acetate Tablet in shortage?
Pfizer has let the FDA know that they are permanently stopping the manufacturing of their brand-name version of this medication, Provera. This affects two specific strengths: the 10 mg tablets, which Pfizer expects to pull from sale around September 2026, and the 2.5 mg tablets, which are expected to be withdrawn from sale in early October 2026. No specific reason was shared publicly for why Pfizer made this decision — just that they are discontinuing production of these particular products.
It's worth knowing that this report only covers Pfizer's Provera tablets. Other manufacturers may make their own versions of medroxyprogesterone acetate and are listed separately on this page.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Medroxyprogesterone Acetate Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Medroxyprogesterone Acetate Tablet?
Medroxyprogesterone acetate tablets are currently listed on the FDA shortage report, and I want to walk you through what that means for you.
The report covers both the 2.5 mg and 10 mg tablets, and neither strength has an available source from the manufacturer that filed this record (Pfizer, maker of the brand Provera). The reason listed is that this manufacturer is discontinuing production — the 10 mg is expected to be withdrawn from sale around September 2026, and the 2.5 mg around early October 2026. Because this is a discontinuation, the supply problem from this maker may be permanent, which makes a conversation with your prescriber the right next step.
This report reflects only one manufacturer, and the same medicine is still made by other companies. Please don't make any changes on your own.
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers and other makers — the same medicine (medroxyprogesterone acetate) is listed from Teva and Mylan in 2.5 mg and 10 mg, though it may not be in local stock.
- If your exact tablet can't be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Medroxyprogesterone Acetate Tablet?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Medroxyprogesterone Acetate Tablet is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Provera | MEDROXYPROGESTERONE ACETATE 5 mg/1 | Tablet · Oral | Pharmacia & Upjohn Company LLC | 00009-0287-01 |
| Medroxyprogesterone Acetate | MEDROXYPROGESTERONE ACETATE 10 mg/1 | Tablet · Oral | Teva Pharmaceuticals USA, Inc. | 00555-0779-02 |
| Medroxyprogesterone Acetate | MEDROXYPROGESTERONE ACETATE 2.5 mg/1 | Tablet · Oral | Teva Pharmaceuticals USA, Inc. | 00555-0872-02 |
| Medroxyprogesterone Acetate | MEDROXYPROGESTERONE ACETATE 5 mg/1 | Tablet · Oral | Teva Pharmaceuticals USA, Inc. | 00555-0873-02 |
| Medroxyprogesterone Acetate | MEDROXYPROGESTERONE ACETATE 10 mg/1 | Tablet · Oral | A-S Medication Solutions | 50090-0166-00 |
| Medroxyprogesterone Acetate | MEDROXYPROGESTERONE ACETATE 2.5 mg/1 | Tablet · Oral | A-S Medication Solutions | 50090-0490-02 |
| Medroxyprogesterone Acetate | MEDROXYPROGESTERONE ACETATE 5 mg/1 | Tablet · Oral | A-S Medication Solutions | 50090-0491-01 |
| Medroxyprogesterone Acetate | MEDROXYPROGESTERONE ACETATE 10 mg/1 | Tablet · Oral | PD-Rx Pharmaceuticals, Inc. | 55289-0160-05 |
| Medroxyprogesterone Acetate | MEDROXYPROGESTERONE ACETATE 2.5 mg/1 | Tablet · Oral | Mylan Pharmaceuticals Inc. | 59762-0055-01 |
| Medroxyprogesterone Acetate | MEDROXYPROGESTERONE ACETATE 10 mg/1 | Tablet · Oral | Mylan Pharmaceuticals Inc. | 59762-0056-01 |
| Medroxyprogesterone Acetate | MEDROXYPROGESTERONE ACETATE 5 mg/1 | Tablet · Oral | Mylan Pharmaceuticals Inc. | 59762-0058-01 |
| Medroxyprogesterone Acetate | MEDROXYPROGESTERONE ACETATE 10 mg/1 | Tablet · Oral | American Health Packaging | 60687-0105-21 |
Alternative dosage forms of Medroxyprogesterone Acetate
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 22 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Medroxyprogesterone Acetate 2.5 mg | Teva | 100 tablets | $0.116 | AB | Availability likely |
| medroxyprogesterone acetate 2.5 mg | Mylan | 100 tablets | $0.116 | AB | Availability likely |
| Medroxyprogesterone Acetate 10 mg | Teva | 100 tablets | $0.152 | AB | Availability likely |
| medroxyprogesterone acetate 10 mg | Mylan | 100 tablets | $0.152 | AB | Availability likely |
| Medroxyprogesterone Acetate 10 mg | American | 30 tablets | $0.152 | AB | Availability likely |
| Provera 2.5 mg | Pharmacia | 100 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 2.5 mg | A-S | 10 tablets | — | AB | Discontinued |
| Medroxyprogesterone Acetate 2.5 mg | Bryant | 100 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 2.5 mg | Coupler | 30 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 2.5 mg | REMEDYREPACK | 50 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 2.5 mg | PD-Rx | 30 tablets | — | AB | FDA listed |
| Provera 10 mg | Pharmacia | 100 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 10 mg | A-S | 10 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 10 mg | Northwind | 30 tablets | — | AB | FDA listed |
| Medroxyprogesterone 10 mg | PharmPak, | 5 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 10 mg | PD-Rx | 5 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 10 mg | Proficient | 10 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 10 mg | Bryant | 10 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 10 mg | Bryant | 100 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 10 mg | NuCare | 10 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 10 mg | Preferred | 10 tablets | — | AB | FDA listed |
| Medroxyprogesterone Acetate 10 mg | REMEDYREPACK | 30 tablets | — | AB | Discontinued |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Medroxyprogesterone Acetate Tablet — that fall in the same broad treatment class (progestational agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other urology shortages
Medroxyprogesterone Acetate Tablet shortage FAQs
Is Medroxyprogesterone Acetate Tablet in shortage?
Which products are affected?
When will Medroxyprogesterone Acetate Tablet be available again?
Can I still get Medroxyprogesterone Acetate somewhere?
What should I do if I take Medroxyprogesterone Acetate Tablet?
Still have a question about the Medroxyprogesterone Acetate Tablet shortage?
Ask a pharmacist about this shortage →View Medroxyprogesterone Acetate Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.